Skip to main content
Premium Trial:

Request an Annual Quote

Myconostica Gets OK to Sell Fungal Dx in Canada

NEW YORK (GenomeWeb News) – Medical diagnostic company Myconostica said yesterday that it has received a license from Health Canada to sell its Aspergillus molecular diagnostic test in Canada.

Myconostica's MycAssay Aspergillus detects Aspergillus DNA in lower respiratory tract samples. Results of the test aid physicians in diagnosing immunocompromised patients suspected of having an infection caused by the fungus.

When MycAssay is used in conjunction with Myconostica's extraction system, MycXtra, a result can be obtained within three hours of sample receipt, the company said.

In conjunction with the announcement, Myconostica, based in Manchester, UK, also said that it has signed an agreement with Inverness Medical Canada, a subsidiary of Inverness Medical Innovations, to exclusively distribute Myconostica's products in Canada.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.